Survival and prognostic factors for adrenocortical carcinoma: A single institution experience

BMC Urology

Volumn 15, Issue 1, 2015, Pages

  Loncar, Zlatibor ^a   Djukic, Vladimir ^a   Zivaljevic, Vladan ^a   Pekmezovic, Tatjana ^a   Diklic, Aleksandar ^a   Tatic, Svetislav ^a   Dundjerovic, Dusko ^a   Olujic, Branislav ^a   Slijepcevic, Nikola ^a   Paunovic, Ivan ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Adrenal gland; Carcinoma; Cortex; Mitotane; Surgery; Survival

Indexed keywords

MITOTANE;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DEMOGRAPHY; DRUG EFFECT; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME; YOUNG ADULT; ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; AGE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; EVALUATION STUDY; KAPLAN MEIER METHOD; MORTALITY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR INVASION;

ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ADRENOCORTICAL CARCINOMA; ADULT; AGE FACTORS; AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEX FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84938981844     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/s12894-015-0038-1     Document Type: Article

References (35)

1. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130-3136.
2. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49:2579-86.
3. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, et al. Adrenocortical carcinomas: surgical trends and results of a 253 patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25:891-7.
4. Tauchmanovà L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A, et al. Adrenocortical carcinomas: twelve-year prospective experience. World J Surg. 2004;28:896-903.
5. Kerkhofs TM, Ettaieb MH, Verhoeven RH, Kaspers GJ, Tissing WJ, Loeffen J, et al. Adrenocortical carcinoma in children: First population based clinicopathological study with long-term follow-up. Oncol Rep. 2014;32:2836-44.
6. Keskin S, Tas F, Vatansever S. Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome. Urol Int. 2013;90:435-438.
7. Dong D, Li H, Yan W, Ji Z, Mao Q. Surgical management and clinical prognosis of adrenocortical carcinoma. Urol Int. 2012;88:400-404.
8. Dy BM, Strajina V, Cayo AK, Richards ML, Farley DR, Grant CS, et al. Surgical Resection of Synchronously Metastatic Adrenocortical Cancer. Ann Surg Oncol. 2015;22:146-51.
9. Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255:363-9.
10. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003;169:5-11.
11. Ferreira U, Nardi Pedro R, Matheus WE, Prudente A, Mendonça Borges G, Rodrigues Netto Jr N. Open surgical treatment of right-sided adrenal carcinomas >15 cm. Urol Int. 2007;78:46-9.
12. Cooper AB, Habra MA, Grubbs EG, Bednarski BK, Ying AK, Perrier ND, et al. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma? Surg Endosc. 2013;27:4026-32.
13. Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg. 2010;34:1380-5.
14. Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012;152:1150-7.
15. Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, et al. German Adrenocortical Carcinoma Registry Group. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010;58:609-15.
16. Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009;115:2816-23.
17. Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:4501-4.
18. Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:192-7.
19. Tritos NA, Cushing GW, Heatley G, Libertino JA. Clinical features and prognostic factors associated with adrenocortical carcinoma: Lahey Clinic Medical Center experience. Am Surg. 2000;66:73-79.
20. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719-26.
21. Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ. Adrenocortical carcinoma: a single institution experience. Am Surg. 2005;71:90-94.
22. Ohwada S, Izumi M, Kawate S, Hamada K, Toya H, Togo N, et al. Surgical outcome of stage III and IV adrenocortical carcinoma. Jpn J Clin Oncol. 2007;37:108-13.
23. Turbendian HK, Strong VE, Hsu M, Ghossein RA, Fahey TJ 3rd. Adrenocortical carcinoma: the influence of large vessel extension. Surgery. 2010;148:1057-1064.
24. Mihai R, Iacobone M, Makay O, Moreno P, Frilling A, Kraimps JL, et al. Outcome of operation in patients with adrenocortical cancer invading the inferior vena cava - a European Society of Endocrine Surgeons (ESES) survey. Langenbecks Arch Surg. 2012;397:225-31.
25. Hermsen IG, Kerkhofs TM, den Butter G, Kievit J, van Eijck CH, van Dijkum EJ N, et al. Surgery in adrenocortical carcinoma: Importance of national cooperation and centralized surgery. Surgery. 2012;152:50-6.
26. Lombardi CP, Raffaelli M, Boniardi M, De Toma G, Marzano LA, Miccoli P, et al. Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbecks Arch Surg. 2012;397:201-7.
27. Kerkhofs TM, Verhoeven RH, Bonjer HJ, van Dijkum EJ, Vriens MR, De Vries J, et al. Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data. Eur J Endocrinol. 2013;16:83-9.
28. Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4759-67.
29. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372-80.
30. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17:263-70.
31. Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, et al. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol. 2014;65:832-8.
32. Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:181-91.
33. Hubalewska-Dydejczyk A, Jabrocka-Hybel A, Pach D, Gilis-Januszewska A, Sokolowski G. Current and future medical therapy, and the molecular features of adrenocortical cancer. Recent Pat Anticancer Drug Discov. 2012;7:132-45.
34. Tacon LJ, Prichard RS, Soon PS, Robinson BG, Clifton-Bligh RJ, Sidhu SB. Current and emerging therapies for advanced adrenocortical carcinoma. Oncologist. 2011;16:36-48.
35. Volante M, Buttigliero C, Greco E, Berruti A, Papotti M. Pathological and molecular features of adrenocortical carcinoma: an update. J Clin Pathol. 2008;61:787-93.